Of course it would be priced at a premium to generics.
On partnering, the point is biodel's flop may push potential partners to wait for more data rather than paying up earlier to secure the program. Had biodel reported blow out data and signed a fat deal I believe it would have pushed the runners up to run to halo.
And likewise, I try to not assume success too early. For an investor with wide eyes its too easy to assume success. Nice thing about halo is they have many shots on goal and success isn't contingent on any one.
Market Data 
Markets 
AI
